 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Salix Pharmaceuticals, Ltd. (SLXP) acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States.
The company offers XIFAXAN tablets for the treatment of patients with travelers diarrhea, and for overt hepatic encephalopathy; MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; APRISO for the maintenance of remission of ulcerative colitis; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; and SOLESTA for the treatment of fecal incontinence; DEFLUX for the treatment of vesicoureteral reflux.
It also provides FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO for the treatment of mildly to moderately active ulcerative colitis in males; and METOZOLV ODT for the treatment of symptomatic documented gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine Tablets, which are used as adjunct for the prevention of rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases.
In addition, the company provides DIURIL for the treatment of hypertension and also as adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney diseases; and COLAZAL for mildly to moderately active ulcerative colitis.
Shares are consolidating in a bullish "cup & handle" and higher share prices are expected for this stock.
52-Week Trading Range: $43.70 - $90.73
Entry Point: $89.80
Stop Loss: $84.73
Target Price: $98.50
We are taking profits on SLXP after it hit our target price. However, this stock is expected to go higher. If you elect to stay in the stock, raise your stop loss to $98.00 to protect your gains!
